Zahi I Mitri (Zahi Mitri)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Topics

Metastatic Breast Cancer

Squamous Cell Carcinoma

High Throughput

Top Venues

NPJ precision oncology

Nature communications

JCO precision oncology

Journal of translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Raoul Charles Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Zahi I Mitri, Carlo Palmieri, Linnea I Chap, Paul Richards, William J Gradishar, Sagar Sardesai, Jason Melear, Joyce O'Shaughnessy, Patrick J Ward, Pavani Chalasani, Tobias Arkenau, Richard D Baird, Rinath M Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G Krebs
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature communications 14 (1) (2023)
Malinda T West, Shaun M Goodyear, Evthokia A Hobbs, Andy Kaempf, Thomas Kartika, Jessica Ribkoff, Brie Chun, Zahi I Mitri
Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer. The oncologist (2023)
Raoul Charles Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Zahi I Mitri, Carlo Palmieri, Linnea I Chap, Paul Richards, William J Gradishar, Sagar Sardesai, Jason Melear, Joyce O'Shaughnessy, Patrick J Ward, Pavani Chalasani, Tobias Arkenau, Richard D Baird, Rinath M Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G Krebs
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature communications 14 (1) (2023)
Allen Li, Shaun Goodyear, Cristina Fuss, Zahi I Mitri
Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. JCO precision oncology 5 (2022)
Zahi I Mitri, Nour Abuhadra, Shaun M Goodyear, Evthokia A Hobbs, Andy Kaempf, Alastair M Thompson, Stacy L Moulder
Impact of TP53 mutations in Triple Negative Breast Cancer. NPJ precision oncology 6 (1) (2022)
Allen Li, Jamie M Keck, Swapnil Parmar, Janice Patterson, Marilyne Labrie, Allison L Creason, Brett E Johnson, Molly Downey, George Thomas, Carol Beadling, Laura M Heiser, Annette Kolodzie, Alexander R Guimaraes, Christopher L Corless, Joe W Gray, Gordon B Mills, Raymond C Bergan, Zahi I Mitri
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ precision oncology 5 (1) (2021)
Marilyne Labrie, Allen Li, Allison L Creason, Courtney Betts, Jamie Keck, Brett E Johnson, Shamilene Sivagnanam, Christopher Boniface, Hongli Ma, Aurora Blucher, Young Hwan Chang, Koei Chin, Jacqueline Vuky, Alexander R Guimaraes, Molly Downey, Jeong Youn Lim, Lina Gao, Kiara Siex, Swapnil Parmar, Annette Kolodzie, Paul T Spellman, Jeremy Goecks, Lisa M Coussens, Christopher L Corless, Raymond C Bergan, Joe W Gray, Gordon B Mills, Zahi I Mitri
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. NPJ precision oncology 5 (1) (2021)
Zahi I Mitri, Swapnil Parmar, Brett Johnson, Annette Kolodzie, Jamie M Keck, Max Morris, Alexander R Guimaraes, Brooke R Beckett, Uma Borate, Charles D Lopez, Kathleen A Kemmer, Joshi J Alumkal, Tomasz M Beer, Christopher L Corless, Gordon B Mills, Joe W Gray, Raymond C Bergan
Implementing a comprehensive translational oncology platform: from molecular testing to actionability. Journal of translational medicine 16 (1) (2018)